Literature DB >> 12400855

Design and synthesis of type-III mimetics of ShK toxin.

Jonathan B Baell1, Andrew J Harvey, Raymond S Norton.   

Abstract

ShK toxin is a structurally defined, 35-residue polypeptide which blocks the voltage-gated Kv1.3 potassium channel in T-lymphocytes and has been identified as a possible immunosuppressant. Our interest lies in the rational design and synthesis of type-III mimetics of protein and polypeptide structure and function. ShK toxin is a challenging target for mimetic design as its binding epitope consists of relatively weakly binding residues, some of which are discontinuous. We discuss here our investigations into the design and synthesis of 1st generation, small molecule mimetics of ShK toxin and highlight any principles relevant to the generic design of type-III mimetics of continuous and discontinuous binding epitopes. We complement our approach with attempted pharmacophore-based database mining.

Mesh:

Substances:

Year:  2002        PMID: 12400855     DOI: 10.1023/a:1020214720560

Source DB:  PubMed          Journal:  J Comput Aided Mol Des        ISSN: 0920-654X            Impact factor:   3.686


  18 in total

1.  Side-chain flexibility in proteins upon ligand binding.

Authors:  R Najmanovich; J Kuttner; V Sobolev; M Edelman
Journal:  Proteins       Date:  2000-05-15

Review 2.  Potassium channels in T lymphocytes: toxins to therapeutic immunosuppressants.

Authors:  K G Chandy; M Cahalan; M Pennington; R S Norton; H Wulff; G A Gutman
Journal:  Toxicon       Date:  2001-09       Impact factor: 3.033

Review 3.  Peptidomimetic design.

Authors:  A S Ripka; D H Rich
Journal:  Curr Opin Chem Biol       Date:  1998-08       Impact factor: 8.822

Review 4.  Non-peptide ligands for peptide receptors.

Authors:  R M Freidinger
Journal:  Trends Pharmacol Sci       Date:  1989-07       Impact factor: 14.819

5.  Selective blockade of T lymphocyte K(+) channels ameliorates experimental autoimmune encephalomyelitis, a model for multiple sclerosis.

Authors:  C Beeton; H Wulff; J Barbaria; O Clot-Faybesse; M Pennington; D Bernard; M D Cahalan; K G Chandy; E Béraud
Journal:  Proc Natl Acad Sci U S A       Date:  2001-11-20       Impact factor: 11.205

6.  The development of a simple empirical scoring function to estimate the binding constant for a protein-ligand complex of known three-dimensional structure.

Authors:  H J Böhm
Journal:  J Comput Aided Mol Des       Date:  1994-06       Impact factor: 3.686

7.  Roles of key functional groups in omega-conotoxin GVIA synthesis, structure and functional assay of selected peptide analogues.

Authors:  J P Flinn; P K Pallaghy; M J Lew; R Murphy; J A Angus; R S Norton
Journal:  Eur J Biochem       Date:  1999-06

8.  Substituted (1,2-diarylethyl)amide acyl-CoA:cholesterol acyltransferase inhibitors: effect of polar groups on in vitro and in vivo activity.

Authors:  J W Clader; J G Berger; R E Burrier; H R Davis; M Domalski; S Dugar; T P Kogan; B Salisbury; W Vaccaro
Journal:  J Med Chem       Date:  1995-05-12       Impact factor: 7.446

9.  ShK-Dap22, a potent Kv1.3-specific immunosuppressive polypeptide.

Authors:  K Kalman; M W Pennington; M D Lanigan; A Nguyen; H Rauer; V Mahnir; K Paschetto; W R Kem; S Grissmer; G A Gutman; E P Christian; M D Cahalan; R S Norton; K G Chandy
Journal:  J Biol Chem       Date:  1998-12-04       Impact factor: 5.157

10.  Pharmacological characterization of five cloned voltage-gated K+ channels, types Kv1.1, 1.2, 1.3, 1.5, and 3.1, stably expressed in mammalian cell lines.

Authors:  S Grissmer; A N Nguyen; J Aiyar; D C Hanson; R J Mather; G A Gutman; M J Karmilowicz; D D Auperin; K G Chandy
Journal:  Mol Pharmacol       Date:  1994-06       Impact factor: 4.436

View more
  5 in total

Review 1.  K+ channel modulators for the treatment of neurological disorders and autoimmune diseases.

Authors:  Heike Wulff; Boris S Zhorov
Journal:  Chem Rev       Date:  2008-05       Impact factor: 60.622

Review 2.  Discovery of KV 1.3 ion channel inhibitors: Medicinal chemistry approaches and challenges.

Authors:  Špela Gubič; Louise A Hendrickx; Žan Toplak; Maša Sterle; Steve Peigneur; Tihomir Tomašič; Luis A Pardo; Jan Tytgat; Anamarija Zega; Lucija P Mašič
Journal:  Med Res Rev       Date:  2021-05-01       Impact factor: 12.944

3.  Structurally minimized mu-conotoxin analogues as sodium channel blockers: implications for designing conopeptide-based therapeutics.

Authors:  Tiffany S Han; Min-Min Zhang; Aleksandra Walewska; Pawel Gruszczynski; Charles R Robertson; Thomas E Cheatham; Doju Yoshikami; Baldomero M Olivera; Grzegorz Bulaj
Journal:  ChemMedChem       Date:  2009-03       Impact factor: 3.466

Review 4.  Mu-conotoxins as leads in the development of new analgesics.

Authors:  Raymond S Norton
Journal:  Molecules       Date:  2010-04-19       Impact factor: 4.411

Review 5.  Bioactive Mimetics of Conotoxins and other Venom Peptides.

Authors:  Peter J Duggan; Kellie L Tuck
Journal:  Toxins (Basel)       Date:  2015-10-16       Impact factor: 4.546

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.